ASX Filings

Notice of Annual General Meeting and Proxy Form

October 28, 2016

Opthea receives $2.6M R&D tax incentive

October 17, 2016

Appendix 3B

October 10, 2016

Opthea Ph1 wAMD data presented at EURETINA 2016

September 12, 2016

Appendix 4G and Corporate Governance Statement 2016

August 29, 2016

Appendix 4E and Annual Report 2016

August 29, 2016

Opthea to Present at Ophthalmology Innovation Summit in US

August 8, 2016

Opthea reports positive data from Phase 1 wet AMD Trial

July 26, 2016

Opthea to Host Conference Call Update on wetAMD Trial

July 25, 2016

Change of Director's Interest Notice - MB

July 5, 2016